CompletedNCT02519543
Insulin Resistance Treatment for Difficult-to-Treat Bipolarity
About this title
Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder
Read the official source — NCT02519543Researchers compared Metformin and placebo to find out how the approaches affected depression symptoms in people with bipolarity.
Medication studyAges 18+United States + Canada
Understand this study
What did researchers investigate?
Researchers compared Metformin and placebo to find out how the approaches affected depression symptoms in people with bipolarity.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Pittsburgh and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Cynthia Calkin
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT02519543
- Official title
Show the full official title
Treating Insulin Resistance to Improve Outcome in Refractory Bipolar Disorder: a Randomized, Double-blind, Placebo-control Study of the Efficacy of Metformin in Patients With Insulin Resistance and Non-remitting Bipolar Illness
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Pittsburgh, United States · Halifax, Canada
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Metformin and placebo to find out how the approaches affected depression symptoms in people with bipolarity.
Who is behind this study?
The study sponsor is Cynthia Calkin.
Did this study involve medication?
Yes. The study involved medication, including Placebo and Metformin.
Who was this study for?
Listed age limits: from 18 years.
